Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Change in Accured Expenses (2016 - 2025)

Aethlon Medical filings provide 15 years of Change in Accured Expenses readings, the most recent being $248736.0 for Q1 2025.

  • On a quarterly basis, Change in Accured Expenses rose 1118.7% to $248736.0 in Q1 2025 year-over-year; TTM through Mar 2025 was -$53360.0, a 134.06% decrease, with the full-year FY2025 number at -$53360.0, down 134.06% from a year prior.
  • Change in Accured Expenses hit $248736.0 in Q1 2025 for Aethlon Medical, up from -$397466.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $540780.0 in Q1 2022 to a low of -$397466.0 in Q4 2024.
  • Median Change in Accured Expenses over the past 5 years was -$25892.0 (2023), compared with a mean of $5254.5.
  • Biggest five-year swings in Change in Accured Expenses: crashed 1435.09% in 2024 and later surged 1118.7% in 2025.
  • Aethlon Medical's Change in Accured Expenses stood at -$69219.0 in 2021, then skyrocketed by 540.01% to $304572.0 in 2022, then plummeted by 108.5% to -$25892.0 in 2023, then crashed by 1435.09% to -$397466.0 in 2024, then skyrocketed by 162.58% to $248736.0 in 2025.
  • The last three reported values for Change in Accured Expenses were $248736.0 (Q1 2025), -$397466.0 (Q4 2024), and -$228406.0 (Q3 2024) per Business Quant data.